Premium
5‐Lipoxygenase expression in benign and malignant canine prostate tissues *
Author(s) -
Goodman L. A.,
Jarrett C. L.,
Krunkosky T. M.,
Budsberg S. C.,
Northrup N. C.,
Saba C. F.,
LeRoy B. E.
Publication year - 2011
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2010.00245.x
Subject(s) - immunohistochemistry , prostate , hyperplasia , stromal cell , pathology , prostatitis , pathogenesis , prostate cancer , apoptosis , cancer research , prostatic diseases , medicine , biology , cancer , biochemistry
5‐Lipoxygenase (5‐LO) is overexpressed in human prostate carcinomas (PCs), and its inhibition decreases proliferation and induces apoptosis in prostate cancer cell lines. We hypothesized that 5‐LO would be overexpressed in canine PC compared with benign prostate tissue and may be important in the pathogenesis of the disease. Immunoblot analysis of canine PC and benign prostatic hyperplasia (BPH) tissues demonstrated 5‐LO expression in both. 5‐LO immunohistochemical staining was not significantly different within the stromal or epithelial components of canine primary PC, BPH or suppurative prostatitis, suggesting that differential expression of this enzyme does not occur in these conditions. The percentage of tumour cells expressing 5‐LO was significantly lower in metastatic PC lesions compared with primary PC ( P < 0.0001). This decreased expression may indicate down‐regulation or altered expression of the enzyme with progression of canine PC to a metastatic phenotype.